Ligand Pharmaceuticals Future Growth
Future criteria checks 1/6
Ligand Pharmaceuticals's earnings are forecast to decline at 4.3% per annum while its annual revenue is expected to grow at 15.1% per year. EPS is expected to decline by 8.9% per annum.
Key information
-4.3%
Earnings growth rate
-8.9%
EPS growth rate
Pharmaceuticals earnings growth | 20.6% |
Revenue growth rate | 15.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 12 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 192 | N/A | 73 | N/A | 1 |
12/31/2025 | 158 | 53 | 78 | N/A | 3 |
12/31/2024 | 137 | 29 | 49 | N/A | 4 |
12/31/2023 | 131 | 54 | -4 | 50 | N/A |
9/30/2023 | 154 | 21 | 90 | 95 | N/A |
6/30/2023 | 180 | 41 | 99 | 108 | N/A |
3/31/2023 | 204 | 51 | 105 | 120 | N/A |
12/31/2022 | 196 | -5 | 120 | 138 | N/A |
9/30/2022 | 183 | 23 | 95 | 112 | N/A |
6/30/2022 | 188 | 27 | 97 | 112 | N/A |
3/31/2022 | 223 | 45 | 110 | 120 | N/A |
12/31/2021 | 242 | 76 | 71 | 79 | N/A |
9/30/2021 | 275 | 68 | 45 | 52 | N/A |
6/30/2021 | 252 | 48 | 37 | 44 | N/A |
3/31/2021 | 208 | 39 | 42 | 48 | N/A |
12/31/2020 | 164 | 7 | 51 | 55 | N/A |
9/30/2020 | 143 | -16 | 41 | 47 | N/A |
6/30/2020 | 126 | -25 | 24 | 28 | N/A |
3/31/2020 | 110 | -61 | -60 | -58 | N/A |
12/31/2019 | 120 | 629 | 781 | -29 | N/A |
9/30/2019 | 153 | 594 | 812 | 11 | N/A |
6/30/2019 | 174 | 677 | 846 | 44 | N/A |
3/31/2019 | 239 | 764 | 980 | 179 | N/A |
12/31/2018 | 251 | 143 | 183 | 194 | N/A |
9/30/2018 | 242 | 179 | 198 | 193 | N/A |
6/30/2018 | 230 | 120 | 196 | 193 | N/A |
3/31/2018 | 168 | 53 | 135 | 130 | N/A |
12/31/2017 | 141 | 13 | 93 | 89 | N/A |
9/30/2017 | 129 | 16 | N/A | 78 | N/A |
6/30/2017 | 117 | 9 | N/A | 69 | N/A |
3/31/2017 | 109 | -3 | N/A | 69 | N/A |
12/31/2016 | 109 | -2 | N/A | 61 | N/A |
9/30/2016 | 92 | 7 | N/A | 56 | N/A |
6/30/2016 | 88 | 205 | N/A | 48 | N/A |
3/31/2016 | 87 | 235 | N/A | 47 | N/A |
12/31/2015 | 72 | 230 | N/A | 42 | N/A |
9/30/2015 | 74 | 231 | N/A | 38 | N/A |
6/30/2015 | 71 | 33 | N/A | 32 | N/A |
3/31/2015 | 63 | 11 | N/A | 26 | N/A |
12/31/2014 | 65 | 12 | N/A | 21 | N/A |
9/30/2014 | 56 | 7 | N/A | 22 | N/A |
6/30/2014 | 54 | 8 | N/A | 18 | N/A |
3/31/2014 | 53 | 10 | N/A | 21 | N/A |
12/31/2013 | 49 | 9 | N/A | 21 | N/A |
9/30/2013 | 48 | 10 | N/A | 11 | N/A |
6/30/2013 | 41 | 7 | N/A | 10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGDN's earnings are forecast to decline over the next 3 years (-4.3% per year).
Earnings vs Market: LGDN's earnings are forecast to decline over the next 3 years (-4.3% per year).
High Growth Earnings: LGDN's earnings are forecast to decline over the next 3 years.
Revenue vs Market: LGDN's revenue (15.1% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: LGDN's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LGDN's Return on Equity is forecast to be high in 3 years time